Selected Publications

Academic Article

Year Title Altmetric
2022 Regulation of NKG2D Stress Ligands and Its Relevance in Cancer ProgressionCancers.  14. 2022
2021 A combined treatment regimen of MGMT-modified γδ T cells and temozolomide chemotherapy is effective against primary high grade gliomasScientific Reports.  11. 2021
2021 Phase II clinical trial of one dose of post-transplant cyclophosphamide for graft versus host disease prevention following myeloablative, peripheral blood stem cell, matched-unrelated donor transplantationAmerican Journal of Hematology.  96:E396-E398. 2021
2019 Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell TransplantationBiology of Blood and Marrow Transplantation.  25:1875-1883. 2019
2019 Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost ImplicationsBiology of Blood and Marrow Transplantation.  25:233-238. 2019
2018 Impact of high-dose steroid premedication on the outcome of myeloablative T-cell replete haploidentical peripheral blood stem cell transplantBone Marrow Transplantation.  53:1345-1348. 2018
2018 Clinical-scale manufacturing of γδ T cells for protection against infection and disease recurrence following haploidentical peripheral blood stem cell transplantation and cyclophosphamide gvhd prophylaxisBone Marrow Transplantation.  53:766-769. 2018
2017 Ex vivo T-cell depletion in allogeneic hematopoietic stem cell transplant: Past, present and futureBone Marrow Transplantation.  52:1241-1248. 2017
2017 Correction: In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.PLoS One.  12:e0172640. 2017
2017 Safety of repeated un-manipulated peripheral blood stem cell haploidentical transplant for graft failureBone Marrow Transplantation.  52:157-158. 2017
2016 In vitro pre-clinical validation of suicide gene modified anti-CD33 redirected chimeric antigen receptor T-cells for acute myeloid leukemiaPLoS One.  11. 2016
2016 A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16 + cervical intraepithelial neoplasia 2/3 (CIN2/3)Gynecologic Oncology.  140:245-252. 2016
2016 Effect of HSV-IL12 Loaded Tumor Cell-Based Vaccination in a Mouse Model of High-Grade NeuroblastomaJournal of Immunology Research.  2016. 2016
2016 In vivo expansion and activation of gd T cells as immunotherapy for refractory neuroblastoma A phase 1 studyMedicine.  95. 2016
2015 Modeling Human Severe Combined Immunodeficiency and Correction by CRISPR/Cas9-Enhanced Gene TargetingCell Reports.  12:1668-1677. 2015
2015 Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia 2015
2015 Dynamics of circulating γδ T cell activity in an immunocompetent mouse model of high-grade gliomaPLoS One.  10. 2015
2015 The safety of allogeneic innate lymphocyte therapy for glioma patients with prior cranial irradiation 2015
2014 Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cellsPLoS One.  9. 2014
2014 Cytotoxic and regulatory properties of circulating Vδ1+ γδ t cells: A new player on the cell therapy field?Molecular Therapy.  22:1416-1422. 2014
2014 Improving the safety of cell therapy products by suicide gene transfer.Frontiers in Pharmacology.  5:254. 2014
2014 Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cellsBiology of Blood and Marrow Transplantation.  20:581-586. 2014
2013 DNA Damage Responses and Oxidative Stress in Dyskeratosis CongenitaPLoS One.  8. 2013
2013 CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated Vδ1+ γδ T CellsPLoS One.  8. 2013
2013 Persistence pays off for γδ T-cell therapiesCytotherapy.  15:397-398. 2013
2013 Engineered Drug Resistant γδ T Cells Kill Glioblastoma Cell Lines during a Chemotherapy Challenge: A Strategy for Combining Chemo- and ImmunotherapyPLoS One.  8. 2013
2011 Preclinical evaluation of ex vivo expanded/activated γδ T cells for immunotherapy of glioblastoma multiformeJournal of Neuro-Oncology.  101:179-188. 2011
2010 Glioma cells display complex cell surface topographies that resist the actions of cytolytic effector lymphocytesJournal of Immunology.  185:4793-4803. 2010
2010 Comparison of immune recovery in recipients of unmanipulated vs T-cell-depleted grafts from unrelated donors in a multicenter randomized phase II-III trial (T-cell depletion trial)Bone Marrow Transplantation.  45:587-589. 2010
2009 γδ T cells as immune effectors against high-grade gliomasImmunologic Research.  45:85-95. 2009
2009 Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastomaNeuro-Oncology.  11:357-367. 2009
2008 B-cell enrichment and infusion in CD4+/CD8+ T-cell depleted products for donor innate immune lymphocyte infusion: Is risk of EBV-associated lymphocyte post transplantation lymphoproliferative disease a concern?Bone Marrow Transplantation.  41:995-996. 2008
2007 Long term disease-free survival in acute leukemia patients recovering with increased γδ T cells after partially mismatched related donor bone marrow transplantationBone Marrow Transplantation.  39:751-757. 2007
2006 Characterization of the γδ T cell response to acute leukemia 2006
2005 T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia 2005
2005 Hematologic aspects of myeloablative therapy and bone marrow transplantationJournal of Clinical Laboratory Analysis.  19:47-79. 2005
2005 γδ T cells: A new frontier for immunotherapy?Biology of Blood and Marrow Transplantation.  11:161-168. 2005
2004 Bone marrow transplantation from partially HLA-mismatched family donors for acute leukemia: Single-center experience of 201 patientsBone Marrow Transplantation.  33:389-396. 2004
2003 Efficacy of Therapeutic Group by Telephone for Women with Breast CancerCancer Nursing.  26:439-447. 2003
2002 Assessment of G-CSF stimulated BM hematopoietic stem cells in normal donorsCytotherapy.  4:55-63. 2002
2002 Hematopoietic cellular therapy: Implications for the flow cytometry laboratory 2002
2002 Immunophenotypic and functional recovery following stem-cell transplantationCytotherapy.  4:99-101. 2002
2002 In vitro interactions between γδT cells, DC, and CD4+ T cells; Implications for the immunotherapy of leukemiaCytotherapy.  4:293-304. 2002
2001 In vitro generation of Epstein-Barr virus-specific cytotoxic T cells in patients receiving haplo-identical allogeneic stem cell transplantationJournal of Immunotherapy.  24:312-322. 2001
2001 NON-MHC-restricted cytotoxic cells: Their roles in the control and treatment of leukaemiasBritish Journal of Haematology.  114:11-24. 2001
2001 Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramersBlood.  98:505-512. 2001
2001 Human γδ+ T lymphocytes have in vitro graft vs leukemia activity in the absence of an allogeneic responseBone Marrow Transplantation.  27:601-606. 2001
1999 Expression of CD134 (OX-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host diseaseCytometry.  38:238-243. 1999
1999 Cryopreserved normal macrophages as a control for assays of macrophage function [2] 1999
1999 Influence of T cell depletion method on circulating γδ T cell reconstitution and potential role in the graft-versus-leukemia effectCytotherapy.  1:7-19. 1999
1999 The 2nd Biannual ISHAGE Conference on applications of flow cytometry in blood and marrow stem cell transplantation.Cytotherapy.  1:331-332. 1999
1998 Co-culture of t cell depleted donor cells and leukemic blast cells in the presence of anti-ys antibody stimulates the in vitro proliferation of γδ t cellsExperimental Hematology.  26:775. 1998
1998 Use of dendritic cells and CD4 T-cells to expand yo Tcells for immunotherapyExperimental Hematology.  26:743. 1998
1998 Phenotypic and functional reconstitution of peripheral blood lymphocytes following T cell-depleted bone marrow transplantation from partially mismatched related donorsBone Marrow Transplantation.  21:461-471. 1998
1998 Donor leukocyte infusion for treatment of graft rejection post partially mismatched related donor bone marrow transplantBone Marrow Transplantation.  22:111-113. 1998
1997 Flow cytometric cell sorting combined with molecular chimerism analysis to detect minimal recurrent leukemia: Good news and bad newsBone Marrow Transplantation.  19:1157-1161. 1997
1997 De nova chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplantBone Marrow Transplantation.  19:813-817. 1997
1997 Corrigendum: De novo chronic graft-versus-host disease presenting as hemolytic anemia following partially mismatched related donor bone marrow transplant (Bone Marrow Transplantation (1997) 19 (813-817))Bone Marrow Transplantation.  20:523. 1997
1996 Low incidence of epstein-barr virus associated b cell lymphoproliferative disorders following partially mismatched related donor bone marrow transplantExperimental Hematology.  24:1142. 1996
1996 T lymphocyte reconstitution following preemptive donor leukocyte infusion therapy forpatientsathigh risk for relapse following T cell depleted bone marrow transplantation from a partially mismatched related donorExperimental Hematology.  24:1091. 1996
1996 In vitro expansion and characterization of dendritic cells derived from human bone marrow CD34+ cellsBone Marrow Transplantation.  18:997-1008. 1996
1996 Increased frequency of TCRγδ+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemiaStem Cells and Development.  5:503-509. 1996
1996 Acute rejection of marrow grafts in patients transplanted from a partially mismatched related donor: Clinical and immunologic characteristicsBone Marrow Transplantation.  17:1021-1027. 1996
1995 Characterization of acute bone marrow graft rejection in T cell-depleted, partially mismatched related donor bone marrow transplantationExperimental Hematology.  23:1595-1600. 1995
1995 Responsibilities in point-of-care testing: An institutional perspectiveArchives of Pathology and Laboratory Medicine.  119:886-889. 1995
1995 Current nursing practice of point-of-care laboratory diagnostic testing in critical care units.American Journal of Critical Care.  4:429-434. 1995
1995 Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantationBone Marrow Transplantation.  15:979-981. 1995
1995 Morphologic and functional characteristics of alveolar macrophages following cryopreservationCryobiology.  32:344-357. 1995
1995 Pneumococcal Clearance Function of the Intact Autotransplanted SpleenJAMA Surgery.  130:946-950. 1995
1994 Development of an immunomagnetic separation procedure to deplete V alpha beta-positive T cells from marrow for use in partially mismatched related donor (PMRD) transplantation.Progress in clinical and biological research.  389:541-550. 1994
1994 Use of a closed system for V alpha beta-positive T cell depletion of marrow for use in partially mismatched related donor (PMRD) transplantation.Progress in clinical and biological research.  389:523-532. 1994
1987 Colorectal cancer in animal models-A reviewJournal of Surgical Research.  43:476-487. 1987
1987 Effect of dietary copper on colonic tumor production and aortic integrity in the ratJournal of Surgical Research.  42:503-512. 1987
1985 What to expect when your patient’s scheduled for mitral valve replacementNursing 2010.  15:58-67. 1985
1982 Think you know septic shock?: Read thisNursing 2010.  12:34-43. 1982


Year Title Altmetric
2020 Therapeutic Potential of Cells of the Immune System.  41-67. 2020
2012 γδ T cells in cancer.  23-38. 2012

Research Overview

  • Dr. Lawrence Lamb is a Clinical Laboratory Immunologist and Professor of Medicine specializing in transplantation immunology. He also is cross-appointed as Professor of Pathology and Pediatrics and is boarded by the Oncology Nursing Certification Corporation for Advanced Practice in Oncology Nursing (AOCNS). Dr. Lamb directs the UAB Cell Therapy Laboratory and cGMP Cell Manufacturing Facility in the Section of Bone Marrow Transplant and Cellular Therapy. Dr. Lamb's group was the first to describe homeostatic reconstitution of gamma/delta T cells in patients who receive alpha/beta T cell depleted bone marrow grafts and an association between gamma/delta T cell recovery with disease-free survival in allogeneic bone marrow transplantation patients as well as gamma/delta T cell receptor CDR3 conservation in leukemia patients. He currently directs an independent research program for evaluation and translation of innate cell-based therapies for Glioblastoma Multiforme and has been funded by the NINDS (5R21NS57341), NCI (2 P50 CA097247), Elsa Pardee Foundation, Leukemia and Lymphoma Society. He also held the National Brain Tumor Society's Samuel Gershon Leadership Chair for Glioblastoma Research for 2008-2010. Dr. Lamb's laboratory anticipates the initial clinical trials for this therapy to initiate in late 2013.
  • Full Name

  • Lawrence Lamb